In 2024, the U.S. Drug Enforcement Administration (DEA) indicated which they plan to reclassify cannabis as being a Schedule III drug. This rescheduling will identify that cannabis has authentic clinical uses and may help open the doorway to research on other prospective therapy works by using. A